Last updated 57 days ago
A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)
150 patients around the world
Available in Chile
Hoffmann-La Roche
4Research sites
150Patients around the world
This study is for people with
Lung cancer
Non-small cell lung carcinoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Cohort B1:Complete resection of the primary NSCLC with negative margins.Confirmed stage II to select stage IIIB (T3N2) NSCLC of non-squamous (adenocarcinoma) histology.Eastern cooperative oncology group (ECOG) performance status of 0 or 1.Cohort B2:Evaluation by the operating attending surgeon and involved medical oncologist prior to study enrollment to verify study eligibility for complete surgical resection with curative intent.Pathologically and/or histologically confirmed Stage II-IIIA and IIIB (T3N2 only) NSCLC of non-squamous (adenocarcinoma) histology.Cohorts B1 and B2: Documented ALK fusion.
- Cohort B1:NSCLC of squamous or mixed histology regardless of the presence of an ALK mutationPrior exposure to any systemic anti-cancer therapyCohort B2:NSCLC of squamous or mixed histology regardless of the presence of an ALK mutation.Known sensitivity to any component of alectinib, pemetrexed, cisplatin, or carboplatin.Prior exposure to any systemic anti-cancer therapy.Exclusion Criteria Cohorts B1 and B2: Pregnancy or breastfeeding, or intention of becoming pregnant during the study.
Sites
Centro de Estudios Clínicos SAGA - CECSAGA
Orlandi Oncología
Instituto Nacional Del Cáncer - Chile
James Lind Centro de Investigación del Cáncer - Temuco
StudyHORIZON 2
SponsorHoffmann-La Roche
Conditions
Non-small cell lung carcinoma
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06624059
